TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29728334

Group type: EXPERIMENTAL
Intervention: Alprostadil (2 μg by intracoronary infusion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nitroglycerin (200 μg)
Number of subjects: 57
Study: 26889616

Group type: EXPERIMENTAL
Intervention: Percutaneous RF heat lesion at the lateral branches of S1, S2, S3, and S4 nerve roots and the posterior ramus dorsalis of L5
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham procedure (same as treatment group except for the RF heat lesion)
Number of subjects: 60
Study: 25241364

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone treatment during early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23788684

Group type: EXPERIMENTAL
Intervention: Zoledronic acid infusion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Denosumab injection
Number of subjects: 92
Study: 20921216

Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise training cessation (2 weeks after training)
Number of subjects: 53
Study: 19022156

Group type: EXPERIMENTAL
Intervention: Statins (3‐hydroxy‐3‐methyl‐glutaryl‐CoA reductase inhibitors)
Number of subjects: 63899
Study: 16608809

Group type: EXPERIMENTAL
Intervention: Immediate radiological investigation
Number of subjects: 172

Group type: COMPARATOR
Intervention: Deferred radiological investigation
Number of subjects: 172
Study: 14582813

Group type: EXPERIMENTAL
Intervention: Particulate matter less than or equal to 2.5 microm (PM2.5)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Particulate matter less than or equal to 10 microm (PM10)
Number of subjects: 133
Study: 11032464

Group type: EXPERIMENTAL
Intervention: Amisulpride (400-1200 mg/d)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Haloperidol (10-30 mg/d)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 199

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 199
Study: 9156546

Group type: EXPERIMENTAL
Intervention: School-Based Adolescent Health Care Program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (national sample of urban youths)
Number of subjects: 19
Study: 1940446

Group type: EXPERIMENTAL
Intervention: Low-dose UVB exposure
Number of subjects: 0
Study: 6489694

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 83
Study: 30852536

Group type: EXPERIMENTAL
Intervention: Age-disparate partnerships
Number of subjects: 1306
Study: 30089292

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture with oral essential amino acids (EA + AA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral essential amino acids alone (AA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison between EA + AA and AA
Number of subjects: 48
Study: 27091532

Group type: EXPERIMENTAL
Intervention: Total sleep time (PSG-TST)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Self-reported habitual sleep duration (SR-HSD)
Number of subjects: 147
Study: 25226941

Group type: EXPERIMENTAL
Intervention: Indoor horse riding exercise (60 min/day, 3 days/week for 8 weeks)
Number of subjects: 20
Study: 21628086

Group type: EXPERIMENTAL
Intervention: TACE with polyvinyl alcohol (PVA) particles 47‐90 μm (n=8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TACE with polyvinyl alcohol (PVA) particles >90‐250 μm (n=9)
Number of subjects: 17
Study: 21167033

Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard type invitation
Number of subjects: 417
Study: 18068485

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (a third-generation bisphosphonate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical markers of bone turnover and tumor markers
Number of subjects: 0
Study: 16164495

Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 200 microg/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Midazolam maintenance dose ranging from 37.5 to 100 microg/kg/h
Number of subjects: 23
Study: 15314976

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Vepesid and Cisplatin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (patients who had not undergone inductive chemotherapy)
Number of subjects: 35
Study: 10665467

Group type: EXPERIMENTAL
Intervention: Suicide-related words
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Measures of anxiety, depression, or hopelessness
Number of subjects: 31
Study: 8916629

Group type: EXPERIMENTAL
Intervention: Mood Management (MM) intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Health Education (HE) intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 201

Group type: COMPARATOR
Intervention: 0 mg nicotine gum (placebo)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: History-positive participants
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Independent of depression diagnosis
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: No treatment differences
Number of subjects: 201
Study: 2008293

Group type: EXPERIMENTAL
Intervention: 1% hyaluronan (Healon; HYA) instilled once daily for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile rice paper prosthesis
Number of subjects: 60
Study: 7037155

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum immunotherapy
Number of subjects: 260

Group type: COMPARATOR
Intervention: Surgical treatment alone (Control)
Number of subjects: 260
Study: 30974433

Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive respiratory support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine and postnatal steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General care protocols
Number of subjects: 0
Study: 29651519

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon Q, DQ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional brackets (Titanium Orthos, TO)
Number of subjects: 32
Study: 27735908

Group type: EXPERIMENTAL
Intervention: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with poor course of CHF (n=45)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with favorable course of CHF (n=49)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison of baseline sFas-L levels between CHF patients and control group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ROC analysis of sFas-L levels for cardiovascular risk stratification
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Correlation of left ventricular (LV) ejection fraction with sFas-L concentrations
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Correlation between serum sFas-L concentrations and LV remodeling parameters
Number of subjects: 94
Study: 24222705

Group type: EXPERIMENTAL
Intervention: Breathing movement-measuring device (BMMD) during deep breathing (DB)
Number of subjects: 10
Study: 22526603

Group type: EXPERIMENTAL
Intervention: Physical activity (measured by a four-category index)
Number of subjects: 12403

Group type: COMPARATOR
Intervention: Inactive individuals
Number of subjects: 12403
Study: 19067472

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 3 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg single dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg repeated dosing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 17460560

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 140
Study: 16103328

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied 3 times a week for 16 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo applied 3 times a week for 16 weeks
Number of subjects: 21
Study: 12065555

Group type: EXPERIMENTAL
Intervention: Regimen A (cisplatin, vincristine, and fluorouracil)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Regimen B (cisplatin and continuous-infusion doxorubicin)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stage I patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stage III patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stage IV patients
Number of subjects: 46
Study: 9809084

Group type: EXPERIMENTAL
Intervention: Residents' group (surgeons with less experience)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Residents' group
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Residents' group (with prophylaxis for PONV)
Number of subjects: 167
Study: 8770854

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per year of life saved
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per quality adjusted life-year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness of different interventions
Number of subjects: 0
Study: 2533616

Group type: EXPERIMENTAL
Intervention: Nafarelin, a gonadotropin releasing hormone analog, dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 0
Study: 402093

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31830347

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel 60 mg/m2, cisplatin 60 mg/m2, 5-FU 750 mg/m2 continuous IV infusion)
Number of subjects: 219

Group type: COMPARATOR
Intervention: PF (cisplatin 75 mg/m2, 5-FU 750 mg/m2)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 219

Group type: COMPARATOR
Intervention: PF
Number of subjects: 219
Study: 30452084

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention (n = 669)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Health Education (HE) intervention (n = 672)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Hospitalization (1-3 cumulative hospital days)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Hospitalization (≥4 cumulative hospital days)
Number of subjects: 1341
Study: 28040350

Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Overall population (all insulin regimens)
Number of subjects: 771

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Gla-100 treatment
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Lower baseline DTSQs
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Study
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Lower severe hypoglycemia rate
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c
Number of subjects: 771
Study: 26063677

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 40-60 mg/day for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22772328

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 20619576

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - nurse-led decision counseling session
Number of subjects: 313

Group type: COMPARATOR
Intervention: Standard Intervention (SI) - practice satisfaction survey
Number of subjects: 313
Study: 19966380

Group type: EXPERIMENTAL
Intervention: De Marco Formula (DMF) 15 ml/kg .day i.m. for 10 days, then twice a week until healing or completion of 52 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 118
Study: 17111305

Group type: EXPERIMENTAL
Intervention: Arabinoxylan (15 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (white bread rolls)
Number of subjects: 11
Study: 14964555

Group type: EXPERIMENTAL
Intervention: Ultrasound scissors (group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No ultrasound scissors (group B)
Number of subjects: 76
Study: 11697810

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate + 500 mg calcium (n = 8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 500 mg calcium only (n = 5)
Number of subjects: 13
Study: 9134641

Group type: EXPERIMENTAL
Intervention: Heparin bolus during PTCA
Number of subjects: 10
Study: 8194140

Group type: EXPERIMENTAL
Intervention: Randomised response technique
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Direct questioning
Number of subjects: 1000
Study: 3130756

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 gm intravenous)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Three-dose cefazolin (1 gm intravenous followed by two additional doses, 8 hours apart)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (low-risk group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Three-dose cefazolin
Number of subjects: 100
Study: 31166807

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (n = 21)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 44
Study: 28236680

Group type: EXPERIMENTAL
Intervention: Neurofeedback on frontal alpha asymmetry
Number of subjects: 32

Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 32
Study: 26060321

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COT)
Number of subjects: 40
Study: 23450020

Group type: EXPERIMENTAL
Intervention: Patient-specific cutting guides (PSCGs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 80
Study: 21340666

Group type: EXPERIMENTAL
Intervention: IRI-S (S-1 plus irinotecan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 0
Study: 18219225

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Baseline K(trans)
Number of subjects: 17
Study: 16430743

Group type: EXPERIMENTAL
Intervention: OraDisc (2 mg amlexanox), applied four times a day for 72 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle patches, applied four times a day for 72 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: OraDisc (2 mg amlexanox)
Number of subjects: 52
Study: 15251640

Group type: EXPERIMENTAL
Intervention: Strict insulin therapy (target glucose range, 80 to 120 mg/dL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard insulin therapy (target glucose range, 180 to 220 mg/dL)
Number of subjects: 61
Study: 11421871

Group type: EXPERIMENTAL
Intervention: Octreotide (200 microg t.d.s., subcutaneously, starting 24 hours before ERCP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no octreotide treatment)
Number of subjects: 120
Study: 9285437

Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 49

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 49
Study: 7870912

Group type: EXPERIMENTAL
Intervention: oxiracetam 1600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oxiracetam 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oxiracetam 2400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3095015

Group type: EXPERIMENTAL
Intervention: Sitting position during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Supine position during exercise
Number of subjects: 6
Study: 30044597

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) value on negative biopsies
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) value on positive biopsies
Number of subjects: 122

Group type: COMPARATOR
Intervention: Subjective intensity of diffusion restriction
Number of subjects: 122

Group type: COMPARATOR
Intervention: Hyper-enhancement
Number of subjects: 122

Group type: COMPARATOR
Intervention: Interobserver agreement
Number of subjects: 122
Study: 26578119

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg administered 1 hour before and 1 hour after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no pregabalin)
Number of subjects: 60
Study: 23557492

Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate shampoo
Number of subjects: 274

Group type: COMPARATOR
Intervention: 2% ketoconazole shampoo
Number of subjects: 274
Study: 22497680

Group type: EXPERIMENTAL
Intervention: A priori heparin administration (50 IU/kg) immediately after sheath insertion
Number of subjects: 400

Group type: COMPARATOR
Intervention: Provisional heparin use only if radial artery patency could not be maintained, otherwise no heparin given during the procedure, with a bolus of heparin (50 IU/kg) if needed
Number of subjects: 400
Study: 20185037

Group type: EXPERIMENTAL
Intervention: ESCAPE discharge risk model
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Discharge risk factors for mortality
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Simplified discharge score
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Bootstrap validation of the model
Number of subjects: 423
Study: 18076272

Group type: EXPERIMENTAL
Intervention: Aerobically-trained (T) subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study: 16119039

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Montelukast sodium 10 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12052269

Group type: EXPERIMENTAL
Intervention: Glycoprotein receptor inhibitors (abciximab, eptifibatide, tirofiban) used with aspirin and heparin
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Glycoprotein receptor inhibitors (abciximab, eptifibatide, tirofiban)
Number of subjects: 50000
Study: 10852140

Group type: EXPERIMENTAL
Intervention: Single-factor lifestyle interventions (diet, exercise, smoking cessation, alcohol intake reduction)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multifactorial lifestyle interventions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single-factor and multifactorial lifestyle interventions
Number of subjects: 42
Study: 8813790

Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leucocyte-depleted blood transfusion
Number of subjects: 60
Study: 1424183

Group type: EXPERIMENTAL
Intervention: Selenium 50 micrograms as selenomethionine administered once daily for 2 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2934747

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Inhaled ipratropium bromide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combination of ipratropium and fenoterol
Number of subjects: 48
Study: 31308282

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (sterile saline)
Number of subjects: 100
Study: 29171154

Group type: EXPERIMENTAL
Intervention: Axial dental midline angulation of 3.5°
Number of subjects: 196

Group type: COMPARATOR
Intervention: Pictures with midline canted in the opposite direction of nose and chin deviations
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Canting in the same direction as asymmetric features
Number of subjects: 196
Study: 27306219

Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) orally 1 week before and during S-1 chemotherapy for 5 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving S-1 chemotherapy without cystine and theanine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystine and theanine group
Number of subjects: 0
Study: 24852424

Group type: EXPERIMENTAL
Intervention: Nasally applied cellulose powder
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 22742399

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 510
Study: 20198404

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial repair
Number of subjects: 42

Group type: COMPARATOR
Intervention: Arthroscopic debridement
Number of subjects: 42
Study: 18601306

Group type: EXPERIMENTAL
Intervention: dexmethylphenidate ER 20 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 15816453

Group type: EXPERIMENTAL
Intervention: PEG plus cisapride (10 mg per os thrice per day three days before the procedure and one 10-mg dose on the morning of the procedure)
Number of subjects: 115

Group type: COMPARATOR
Intervention: PEG plus placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PEG plus cisapride
Number of subjects: 115
Study: 12808585

Group type: EXPERIMENTAL
Intervention: Conjoint therapy for partners of alcohol abusers
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Assessment of patient-treatment matching dimensions
Number of subjects: 75
Study: 10566565

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 658

Group type: COMPARATOR
Intervention: Rofecoxib 5 mg once daily
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 8977607

Group type: EXPERIMENTAL
Intervention: Partially attended night time respiratory recording (NTRR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Full polysomnography (PSG)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NTRR
Number of subjects: 76
Study: 31919136

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751